According to the Zhitong Finance App, Hanyu Pharmaceutical (300199.SZ) released a performance forecast for the first three quarters of 2026. Net profit attributable to shareholders of listed companies is expected to be 430 million yuan to 450 million yuan in the first three quarters, an increase of 502.65%-530.68% over the previous year. Net profit attributable to shareholders of listed companies increased sharply year-on-year during the reporting period. The main reason was that the company's API business continued to expand during the reporting period, leading to both revenue and profit growth. At the same time, the company's R&D investment in projects such as the three-target innovative drug HY3003 and small nucleic acid increased dramatically over the same period last year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.